OR5AK2

Across TCGA pan-cancer cohorts, OR5AK2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR5AK2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher OR5AK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5AK2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KICH, COAD, and BRCA are the cancer types where OR5AK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	OS	Median	All	0.161	0.881	<.001	24	view →
COAD	DFS	Median	All	0.164	0.783	<.001	21	view →
BRCA	OS	Median	III,IV	0.157	0.906	<.001	20	view →
BLCA	DFS	Median	All	0.137	0.598	.003	18	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.882	0.662	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR5AK2–KICH (OS)

Open the KICH breakdown →